GlassScriptPhysician profile
Nandheesha Hanumanthappa
NPI 1609195833
$2,512.69
in general payments reported to CMS, 2019-2025
24 companies · $846 in 2025
The $846 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $612 · 2020: $96.31 · 2021: $125 · 2022: $109 · 2023: $260 · 2024: $463 · 2025: $846.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,530 · Education: $39.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,529.88 |
| Education | $39.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $299.87 | 2019-2025 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $277.83 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $221.73 | 2019-2025 | Farxiga |
| Akebia Therapeutics INC | $218.89 | 2019-2024 | Vafseo, Auryxia |
| Vifor Pharma, INC. | $166.05 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $153.17 | 2023-2025 | Acthar |
| Mallinckrodt Enterprises LLC | $137.28 | 2019 | |
| Travere Therapeutics, INC. | $116.51 | 2024-2025 | |
| Ardelyx, INC. | $110.32 | 2024-2025 | Ibsrela |
| Amgen INC. | $103.73 | 2020-2025 | Krystexxa, Tavneos |
| Opko Pharmaceuticals, LLC | $96.99 | 2020-2025 | Rayaldee |
| Fresenius USA Marketing, INC. | $86.51 | 2019-2024 | Velphoro |
| Novartis Pharmaceuticals Corporation | $81.70 | 2023-2025 | |
| Novo Nordisk INC | $74.85 | 2025 | Ozempic, Rybelsus |
| Calliditas Therapeutics US INC. | $72.86 | 2024-2025 | Tarpeyo |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $63.24 | 2019-2023 | Krystexxa |
| Kyowa Kirin, INC. | $47.42 | 2025 | |
| Lilly USA, LLC | $35.25 | 2024-2025 | Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.65 | 2023-2025 | Jardiance |
| Aurinia Pharma U.S., INC. | $28.24 | 2023 | Lupkynis |
| Scpharmaceuticals INC. | $25.80 | 2025 | |
| Apellis Pharmaceuticals, INC. | $25.06 | 2025 | |
| Renalytix Ai, INC. | $22.77 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Janssen Pharmaceuticals, INC | $17.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nandheesha Hanumanthappa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.